| Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy |
TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company's branded franchises, stabilization of the company's generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085. |
globenewswire.com |
2025-05-15 22:12:00 |
Czytaj oryginał (ang.) |
| Why Teva Pharmaceuticals Stock Blasted 6% Higher Today |
A positive change in recommendation from a well-known bank was the fuel propelling Teva Pharmaceutical Industries's (TEVA 5.82%) well higher on Monday. The company, known for being a top producer of generic drugs, saw its share price swell almost 6% as a result. |
fool.com |
2025-05-12 21:02:06 |
Czytaj oryginał (ang.) |
| Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside |
Teva's betting big on biosimilars and specialty drugs, with AUSTEDO and UZEDY leading the charge. Management's $700 million cost-cutting plan is on track, aiming for a 30% operating margin by 2027. Recent FDA wins, like SELARSDI, show Teva's pushing into high-margin markets. |
seekingalpha.com |
2025-05-08 15:33:14 |
Czytaj oryginał (ang.) |
| TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up |
TEVA shares rise despite mixed first-quarter results. Teva lowers the higher end of its 2025 sales guidance while increasing the lower end of its EPS range. |
zacks.com |
2025-05-08 12:50:44 |
Czytaj oryginał (ang.) |
| Why Teva Pharmaceutical Stock Is Soaring Today |
Shares of Teva Pharmaceutical (TEVA 8.44%) are surging on Wednesday. The company's stock is up 9.2% as of 1:15 p.m. |
fool.com |
2025-05-07 18:08:00 |
Czytaj oryginał (ang.) |
| Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says |
The drugmaker reported first-quarter earnings that beat expectations and raised its full-year guidance. |
barrons.com |
2025-05-07 17:01:00 |
Czytaj oryginał (ang.) |
| Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot Momentum |
Teva Pharmaceutical Industries Ltd TEVA stock is trading higher on Wednesday after the company's first-quarter 2025 financial results. Here are the details. |
benzinga.com |
2025-05-07 16:13:19 |
Czytaj oryginał (ang.) |
| Teva CEO Richard Francis on tariffs: Well positioned to maintain guidance despite duties |
Richard Francis, Teva Pharma CEO, joins 'Money Movers' to discuss the company's quarterly earnings results, any pharma shortages in the U.S., and much more. |
youtube.com |
2025-05-07 15:51:55 |
Czytaj oryginał (ang.) |
| Teva Pharma climbs as earnings impress |
Shares in Teva Pharmaceutical Industries (NASDAQ:TEVA) rose 5% after publishing first-quarter earnings, where the Israeli company said US tariffs are expected to have an "immaterial impact". The Tel Aviv-based drugs maker reported revenue of $3.9 billion for the quarter, a 5% increase in local currency terms as key growth products continued to perform well, with operating income swinging to $519 million from a loss of $218 million a year ago. |
proactiveinvestors.com |
2025-05-07 15:34:57 |
Czytaj oryginał (ang.) |
| Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript |
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Q1 2025 Earnings Call May 7, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Richard Francis - President & CEO Eric A. Hughes - EVP, Global R&D and Chief Medical Officer Eli Kalif - EVP & CFO Conference Call Participants David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Ashwani Verma - UBS Investment Bank Christopher Schott - J.P. |
seekingalpha.com |
2025-05-07 14:47:38 |
Czytaj oryginał (ang.) |
| Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say |
While the top- and bottom-line numbers for Teva Pharmaceutical Industries (TEVA) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-05-07 14:36:30 |
Czytaj oryginał (ang.) |
| Teva Pharm first-quarter profit rise tops estimates |
Teva Pharmaceutical Industries reported a slightly larger than expected rise in first-quarter profit, helped by strong sales gains in a trio of its branded drugs to treat migraines, Huntington's disease and schizophrenia. |
reuters.com |
2025-05-07 11:30:26 |
Czytaj oryginał (ang.) |
| Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday? |
The U.S. Food and Drug Administration (FDA) has approved Teva Pharmaceutical Industries Ltd. TEVA and Alvotech's ALVO Selarsdi (ustekinumab-aekn) injection as interchangeable with the reference biologic Johnson & Johnson's JNJ Stelara (ustekinumab). |
benzinga.com |
2025-05-05 15:43:05 |
Czytaj oryginał (ang.) |
| Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy? |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-05 14:55:40 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings |
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Teva Pharmaceutical Industries (TEVA), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025. |
zacks.com |
2025-05-05 14:22:06 |
Czytaj oryginał (ang.) |
| Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab) |
PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn) injection as interchangeable with the reference biologic Stelara® (ustekinumab). As of April 30, 2025, SELARSDI is available and interchangeable in all presentations matching the reference product, including the treatment of adults and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis. |
globenewswire.com |
2025-05-05 11:49:00 |
Czytaj oryginał (ang.) |
| Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now |
When examined over long stretches, stocks stand atop the pedestal in terms of annualized return, relative to all other asset classes. But this doesn't mean the Dow Jones Industrial Average (^DJI -1.33%), S&P 500 (^GSPC 0.13%), and Nasdaq Composite (^IXIC -0.13%) move from Point A to B in a straight line. |
fool.com |
2025-04-21 07:51:00 |
Czytaj oryginał (ang.) |
| Billionaire Sold Broadcom And Bought This Stock That Could Soar 121% |
TEVA has 121% upside from its share price today. Retiring early is possible, and may be easier than you think. |
247wallst.com |
2025-04-16 15:06:13 |
Czytaj oryginał (ang.) |
| 5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility |
For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line. |
fool.com |
2025-04-13 07:06:00 |
Czytaj oryginał (ang.) |
| Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention |
PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address the high unmet need for effective treatments for those living with migraine. |
globenewswire.com |
2025-04-07 11:30:00 |
Czytaj oryginał (ang.) |
| 2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals |
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states |
globenewswire.com |
2025-02-27 10:00:00 |
Czytaj oryginał (ang.) |
| Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder |
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL) announced today that the supplemental New Drug Application (sNDA) for UZEDY extended-release injectable suspension for the maintenance treatment of BP-I in adults has been accepted for filing by the U.S. Food and Drug Administration (FDA). |
globenewswire.com |
2025-02-25 18:00:00 |
Czytaj oryginał (ang.) |
| Teva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript) |
Teva Pharmaceutical Industries Limited (NYSE:TEVA ) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference February 24, 2025 8:00 AM ET Company Participants Christopher Stevo - SVP, IR Eric Hughes - Head of R&D & Chief Medical Officer Vipul Jairath - Professor at Western University Conference Call Participants Umer Raffat - Evercore ISI Ash Verma - UBS David Amsellem - Piper Sandler Jason Gerberry - Bank of America Chris Schulz - J.P. Morgan Operator Good morning or good afternoon all, and welcome to the Duvakitug Anti-TL1A Phase 2b Data Presentation from ECCO. |
seekingalpha.com |
2025-02-24 12:48:09 |
Czytaj oryginał (ang.) |
| Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease |
New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025 PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. |
globenewswire.com |
2025-02-22 04:20:00 |
Czytaj oryginał (ang.) |
| Final Trade: TEVA, JNJ, TJX, BABA |
The final trades of the day with the Fast Money traders. |
youtube.com |
2025-02-21 20:27:24 |
Czytaj oryginał (ang.) |
| Teva Pharma and Alvotech launch US biosimilar to J&J's Stelara |
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States. |
reuters.com |
2025-02-21 08:44:05 |
Czytaj oryginał (ang.) |
| Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S. |
PARSIPPANY, N.J. and REYKJAVÍK, Iceland, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Alvotech (NASDAQ: ALVO) today announced the availability of SELARSDI™ (ustekinumab-aekn) injection in the U.S., a biosimilar to Stelara® (ustekinumab), for the treatment of psoriatic arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership. The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara®, following the expiration of exclusivity for the first interchangeable biosimilar, on April 30, 2025. |
globenewswire.com |
2025-02-21 08:00:00 |
Czytaj oryginał (ang.) |
| Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist |
Though earnings season -- the roughly six-week period each quarter where a majority of S&P 500 companies reveal their latest operating results -- provides plenty of juicy data for investors to sift through, there's arguably no data release more important than quarterly filed Form 13F filings with the Securities and Exchange Commission. |
fool.com |
2025-02-20 07:06:00 |
Czytaj oryginał (ang.) |
| Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO) |
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for duvakitug (anti-TL1A) positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO). |
globenewswire.com |
2025-02-18 18:30:00 |
Czytaj oryginał (ang.) |
| FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea |
Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders. |
investopedia.com |
2025-02-18 13:30:52 |
Czytaj oryginał (ang.) |
| Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept) |
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed in the fourth quarter of 2025. |
globenewswire.com |
2025-02-18 08:00:00 |
Czytaj oryginał (ang.) |
| Teva Pharm CEO calls for faster US generic drug approvals |
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday. |
reuters.com |
2025-02-17 06:42:00 |
Czytaj oryginał (ang.) |
| Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade |
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth. |
seekingalpha.com |
2025-02-11 19:20:43 |
Czytaj oryginał (ang.) |
| Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' |
On Monday, Axsome Therapeutics, Inc. AXSM signed a settlement agreement with Teva Pharmaceuticals Inc TEVA. |
benzinga.com |
2025-02-10 14:33:47 |
Czytaj oryginał (ang.) |
| Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals |
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE. |
businesswire.com |
2025-02-10 04:00:00 |
Czytaj oryginał (ang.) |
| Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now |
Teva Pharmaceuticals Industries Ltd NYSE: TEVA is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line of branded drugs driving growth. |
marketbeat.com |
2025-02-03 13:00:36 |
Czytaj oryginał (ang.) |
| Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An Opportunity |
Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be outperformed, and a desirable entry point for long-term investors. Teva Pharmaceutical's pipeline, including Duvakitug and multiple biosimilars, offers significant growth prospects, with several key Phase 3 milestones and potential launches from 2025 to 2027. |
seekingalpha.com |
2025-01-30 15:35:10 |
Czytaj oryginał (ang.) |
| TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates |
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook. |
zacks.com |
2025-01-30 14:16:09 |
Czytaj oryginał (ang.) |
| Why Teva Pharmaceutical Stock Is Sinking Today |
Shares of Teva Pharmaceutical Industries (TEVA -13.21%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. |
fool.com |
2025-01-29 16:26:45 |
Czytaj oryginał (ang.) |
| Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet |
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 1% on Wednesday. |
benzinga.com |
2025-01-29 15:39:08 |
Czytaj oryginał (ang.) |
| Duvakitug And Teva's Growth: A Game Changer In Pharma |
On December 17, Teva Pharmaceutical Industries Limited reported that duvakitug had shown stunning results in a phase 2b study for the treatment of Crohn's disease and ulcerative colitis. However, a month and a half before this news, the Israeli pharmaceutical company pleased investors by once again beating analysts' expectations by a wide margin. So, Uzedy's sales amounted to $35 million in the third quarter of 2024, increasing more than 16 times year-on-year. |
seekingalpha.com |
2024-12-27 17:21:29 |
Czytaj oryginał (ang.) |
| Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2025 |
Over the last two years, there hasn't been a hotter trend on Wall Street than the rise of artificial intelligence (AI). The ability for AI-powered software and systems to become more proficient at their existing tasks, as well as evolve to learn new jobs over time without human intervention, gives this technology a virtually limitless ceiling and broad-based utility in most industries. |
fool.com |
2024-12-24 06:51:00 |
Czytaj oryginał (ang.) |
| Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). |
globenewswire.com |
2024-12-23 18:30:00 |
Czytaj oryginał (ang.) |
| Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 |
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. |
globenewswire.com |
2024-12-20 18:30:00 |
Czytaj oryginał (ang.) |
| Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases |
Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD). |
benzinga.com |
2024-12-18 16:29:55 |
Czytaj oryginał (ang.) |
| SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study |
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications. |
zacks.com |
2024-12-18 11:25:35 |
Czytaj oryginał (ang.) |
| Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength? |
Teva Pharmaceutical Industries (TEVA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2024-12-18 09:41:18 |
Czytaj oryginał (ang.) |
| TEVA stock soars 26%: What's going on with Teva Pharmaceuticals? |
Teva Pharmaceuticals (NASDAQ: TEVA) and its partner Sanofi (NASDAQ: SNY) have announced groundbreaking results from clinical trials of their drug, duvakitug, for ulcerative colitis and Crohn's disease, two of the most prevalent forms of inflammatory bowel disease (IBD). The announcement, which sent Teva's stock soaring by 26.4% to $20.88 and Sanofi's up 6.7% to $48. |
invezz.com |
2024-12-18 06:32:30 |
Czytaj oryginał (ang.) |
| Overlooked Stock: TEVA |
Teva Pharmaceutical (TEVA) closed at its highest stock price of the year after it and Sanofi (SNY) say their IBD treatment had higher remission in trial. George Tsilis looks at how the development can be the first step in a turnaround for the company. |
youtube.com |
2024-12-17 18:50:01 |
Czytaj oryginał (ang.) |
| Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's |
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn's disease. |
investopedia.com |
2024-12-17 16:25:47 |
Czytaj oryginał (ang.) |
| TD says Spyre has 'superior TL1A program' after Teva data |
TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to its bigger rivals, Spyre has an anti-TL1A monoclonal antibody in its product pipeline, known as SPY002, the analyst tells investors in a research note. TD believes Spyre has the "superior TL1A program" and its combination treatments under development "will further elevate outcomes." Teva and Sanofi's results "further validate TL1A inhibition as a highly promising mechanism" for both ulcerative colitis and Crohn's disease, contends the firm. Spyre Therapeutics +0.105 (+0.43%) Teva +4.32 (+26.18%) Sanofi +3.38 (+7.37%) |
https://thefly.com |
2024-12-17 16:18:32 |
Czytaj oryginał (ang.) |
| Spyre Therapeutics weakness after Teva data a buying opportunity, says BTIG |
BTIG analyst Julian Harrison notes that Teva's (TEVA) enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that "they only own 50% rights to" plus $1B in development and launch milestones. The firm's "main takeaways" for Spyre Therapeutics (SYRE) from today's update from Teva are that strong market demand for anti-TL1A assets has "not faded at all" and the upside potential for SPY002 "looks even further reinforced," as BTIG expects the TL1A constructs that Spyre is developing to "likely leapfrog the broader class both on efficacy and dosing." The firm, which keeps a Buy rating and $70 price target on Spyre shares, views the relative weakness following the duvakitug data as a buying opportunity, the analyst tells investors. Spyre Therapeutics -0.005 (-0.02%) Teva +4.385 (+26.58%) |
https://thefly.com |
2024-12-17 16:03:04 |
Czytaj oryginał (ang.) |
| Teva price target raised to $25 from $23 at BofA |
BofA raised the firm's price target on Teva to $25 from $23 and keeps a Buy rating on the shares. The price target increase reflects the strong Phase 2 update for duvakitug as a treatment for inflammatory bowel disorders, the analyst tells investors in a research note. The firm now forecasts nominal peak sales of roughly $2B, with Teva booking half the profits, based on the strength of the data and the emerging product profile. |
https://thefly.com |
2024-12-17 15:23:59 |
Czytaj oryginał (ang.) |
| Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment |
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies. |
wsj.com |
2024-12-17 13:51:00 |
Czytaj oryginał (ang.) |
| 2 Pharma Stocks to Watch: Pfizer, Teva Pharmaceutical |
Pharma stocks Pfizer Inc (NYSE:PFE) and Teva Pharmaceutical Industries Ltd (NYSE:TEVA) are in the spotlight today. |
schaeffersresearch.com |
2024-12-17 12:24:50 |
Czytaj oryginał (ang.) |
| Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? |
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD). |
benzinga.com |
2024-12-17 11:16:32 |
Czytaj oryginał (ang.) |
| Teva, Sanofi say drug to treat IBD met primary targets |
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals. |
reuters.com |
2024-12-17 09:35:13 |
Czytaj oryginał (ang.) |
| Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease |
Primary endpoints met in ulcerative colitis (UC) and Crohn's disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. |
globenewswire.com |
2024-12-17 09:30:00 |
Czytaj oryginał (ang.) |
| Can Teva Return To All-Time Highs? |
Teva Pharmaceutical stock has rebounded from lows, driven by debt reduction, halted price deflation in generics, and new product launches, making it a strong buy. Teva's innovative branded drugs and biosimilar pipeline, including AUSTEDO and upcoming biosimilars like PROLIA and RANIVISIO, offer substantial growth opportunities. Teva's business has followed a boom and bust cycle. Substantial biologic patent expirations in the coming years point to another boom. |
seekingalpha.com |
2024-12-06 10:00:00 |
Czytaj oryginał (ang.) |
| Pharma firm Teva to divest its business venture in Japan |
Teva Pharmaceutical Industries said on Thursday it will transfer ownership of its business venture that sold generics in Japan to JKI. |
reuters.com |
2024-12-05 20:39:52 |
Czytaj oryginał (ang.) |